Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Editas Medicine, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
6.05
13.7
31.9
20.5
90.7
25.5
19.7
78.1
32.3
40.5
Research and development
57
83.2
90.7
96.9
158
143
175
178
199
90
General and administrative
46.3
50.5
55
64.6
67.6
76.2
70.7
69.7
72
49.9
Operating expenses
103
134
146
161
226
219
246
247
283
201
Operating income
-97.2
-120
-114
-141
-135
-193
-226
-169
-251
-160
Interest expense
0
2.13
Other non-operating income
0.01
-0.39
3.77
7.18
18.9
0.64
5.52
16
14.1
-0.05
Income tax
0
0
0
0
0
Net income
-97.2
-120
-110
-134
-116
-193
-220
-153
-237
-160
EBITDA
-96
-117
-110
-138
-131
-188
-220
-163
-245
-155
EPS, basic
-3.02
-2.98
-2.33
-2.68
-1.98
-2.85
-3.21
-2.02
-2.88
-1.80
EPS, diluted
-3.02
-2.98
-2.33
-2.68
-1.98
-2.85
-3.21
-2.02
-2.88
-1.80
Shares, basic (weighted)
32.2
40.3
47.1
50
58.6
67.6
68.7
76
82.3
88.7
Shares, diluted (weighted)
32.2
40.3
47.1
50
58.6
67.6
68.7
76
82.3
88.7
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
185
147
135
238
140
204
142
124
132
147
Short-term investments
183
234
219
262
296
203
199
138
0
Receivables
0.09
0.68
0.03
0.42
6.05
0.27
5.15
10.2
16.3
15.2
Other current assets
1.77
2.38
5.79
6.29
10.9
7.2
7.34
7.53
3.14
2.07
Total current assets
187
332
375
464
419
507
357
341
289
164
Property, plant and equipment
40.4
39.4
40.2
10.9
14
17.1
15.6
12
14.5
3.54
Lease right-of-use assets
28.8
25.1
26.2
43.6
33.7
32.6
16.1
Long-term investments
110
120
93.1
104
0
Other non-current assets
1.62
1.62
5.38
5.39
4.7
6.81
5.25
8.59
5.22
2.98
Total assets
229
373
420
509
573
677
514
499
342
187
Accounts payable
4.64
4.02
5.33
5.84
6.41
5.05
9.51
8.27
5.49
2.61
Accrued liabilities
17.4
11
12.8
22.1
24
20.2
31.3
34.6
45.9
32.6
Deferred revenue
0.26
13.2
15.7
23.5
20.9
11.3
8.22
8.22
6.22
0
Short-term debt
0
5
5
Total current liabilities
33.1
36.7
35.9
60
58.2
46.9
60.1
63.2
77.2
46.2
Long-term debt
0
52.4
53.6
Lease liabilities
23.3
19.3
16.1
32.9
24.4
20.4
12.1
Other non-current liabilities
0.4
0.32
0.29
0
27.5
0
1.8
3.07
2.82
Total liabilities
94.6
165
184
246
179
124
154
150
207
159
Total debt
0
57.4
58.6
Paid-in capital
320
514
652
812
1,059
1,412
1,442
1,580
1,602
1,656
Retained earnings
-186
-306
-416
-549
-665
-858
-1,078
-1,231
-1,468
-1,629
Other comprehensive income
-0.08
-0.03
0.11
-0.05
-0.49
-3.6
0.2
0.27
0
Shareholders' equity
135
208
236
262
394
554
361
349
134
27.3
Total equity
135
208
236
262
394
554
361
349
134
27.3
Total liabilities and equity
229
373
420
509
573
677
514
499
342
187
Shares outstanding
35.8
44.5
48.8
54.4
62.6
68.4
68.8
81.8
82.7
97.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-97.2
-120
-110
-134
-116
-193
-220
-153
-237
-160
Depreciation and amortization
1.2
2.68
3.25
2.83
3.96
5.05
6.34
6.06
5.81
5.28
Stock-based compensation
16.9
23.4
26.6
27.2
23.2
43.4
29.3
19.8
21.4
10
Change in receivables
0.93
-0.59
0.65
-0.39
-5.63
5.78
-4.88
-5.04
-6.08
1.09
Change in payables
3.25
-1.52
1.78
0.27
0.86
-1.14
4.37
-1.49
-2.29
-2.89
Cash from operations
-50.2
-9.42
-45.7
-40.7
-180
-164
-177
-132
-210
-165
Capital expenditures
-3.49
-2.06
-4.75
-6.17
-7.16
-7.98
-4.12
-4.72
-8.83
-0.61
Purchases of investments
-375
-459
-342
-458
-409
-315
-259
-86.2
0
Sales and maturities of investments
194
411
361
305
362
433
260
257
139
Cash from investing
-3.47
-184
-53.1
12.3
-141
-54.5
114
-3.73
162
139
Debt issued
57
Debt repaid
0
-2.87
Stock issued
97.5
154
76.8
116
204
249
0
117
0
42.8
Cash from financing
97.2
155
86.9
132
224
282
1.28
118
56
40.5
Net change in cash
43.4
-38.7
-11.9
103
-96.2
63.8
-62
-17.9
7.89
13.9
Free cash flow
-53.7
-11.5
-50.5
-46.8
-187
-172
-181
-137
-219
-166
Interest paid
0.47
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.58 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-161.4%
Operating income / revenue.
EBITDA margin
-156.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-157.3%
Net income / revenue.
FCF margin
-256.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-255.0%
Cash from operations / revenue.
Return on equity (ROE)
-70.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.2%
Net income / average total assets.
R&D / revenue
180.7%
Research and development expense / revenue.
Stock-based pay / revenue
18.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.5%
Capital expenditures / revenue.
D&A / revenue
5.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
25.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
27.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-14.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-79.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-57.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-41.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-45.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-20.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
7.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
8.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
8.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.19x
Current assets / current liabilities.
Quick ratio
3.13x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.09x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.53x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
23.5%
Total debt / total assets.
Liabilities / assets
55.6%
Total liabilities / total assets.
Net debt
-$155.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.39
Revenue / diluted weighted shares.
FCF per share
-$1.01
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.00
Cash from operations / diluted weighted shares.
Book value per share
$1.08
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
8.43x
Market cap / revenue.
P/B
3.76x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.76x
Market cap / tangible book value, when positive.
EV/Sales
5.11x
Enterprise value / revenue.
FCF yield
-30.4%
Free cash flow / market cap.
Earnings yield
-18.7%
Net income / market cap (the inverse of P/E).
What was Editas Medicine, Inc.'s revenue in fiscal 2025?
Editas Medicine, Inc. reported revenue of $40.5M for fiscal 2025, 25.4% higher than the year before.
Was Editas Medicine, Inc. profitable in fiscal 2025?
No. It reported a net loss of $160.1M.
How much free cash flow did Editas Medicine, Inc. generate in fiscal 2025?
Cash from operations of $165.2M minus capital expenditures of $607.0K left free cash flow of -$165.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.